ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

Related Keywords

Jamesm Ford ,Megan Craig ,Stanford University ,Cancer Research Group ,Research Group ,Study Summary ,